The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome
Abstract
CONTEXT: Prior mechanistic studies reported that omeprazole decreases the platelet inhibitory effects of clopidogrel, yet the clinical significance of these findings is not clear. OBJECTIVE: To assess outcomes of patients taking clopidogrel with or without a proton pump inhibitor (PPI) after hospitalization for acute coronary syndrome (ACS). DESIGN, SETTING, AND PATIENTS: Retrospective cohort study of 8205 patients with ACS taking clopidogrel after discharge from 127 Veterans Affairs hospitals between October 1, 2003, and January 31, 2006. Vital status information was available for all patients through September 30, 2006. MAIN OUTCOME MEASURES: All-cause mortality or rehospitalization for ACS. RESULTS: Of 8205 patients taking clopidogrel after discharge, 63.9% (n = 5244) were prescribed PPI at discharge, during follow-up, or both and 36.1% (n = 2961) were not prescribed PPI. Death or rehospitalization for ACS occurred in 20.8% (n = 615) of patients taking clopidogrel without PPI and 29.8% (n = 1561) of patients taking clopidogrel plus PPI. In multivariable analyses, use of clopidogrel plus PPI was associated with an increased risk of death or rehospitalization for ACS compared with use of clopidogrel without PPI (adjusted odds ratio [AOR], 1.25; 95% confidence interval [CI], 1.11-1.41). Among patients taking clopidogrel after hospital discharge and prescribed PPI at any point during follow-up (n = 5244), periods of use of clopidogrel plus PPI (compared with periods of use of clopidogrel without PPI) were associated with a higher risk of death or rehospitalization for ACS (adjusted hazard ratio, 1.27; 95% CI, 1.10-1.46). In analyses of secondary outcomes, patients taking clopidogrel plus PPI had a higher risk of hospitalizations for recurrent ACS compared with patients taking clopidogrel without PPI (14.6% vs 6.9%; AOR, 1.86 [95% CI, 1.57-2.20]) and revascularization procedures (15.5% vs 11.9%; AOR, 1.49 [95% CI, 1.30-1.71]), but not for all-cause mortality (19.9% vs 16.6%; AOR, 0.91 [95% CI, 0.80-1.05]). The association between use of clopidogrel plus PPI and increased risk of adverse outcomes also was consistent using a nested case-control study design (AOR, 1.32; 95% CI, 1.14-1.54). In addition, use of PPI without clopidogrel was not associated with death or rehospitalization for ACS among patients not taking clopidogrel after hospital discharge (n = 6450) (AOR, 0.98; 95% CI, 0.85-1.13). CONCLUSION: Concomitant use of clopidogrel and PPI after hospital discharge for ACS was associated with an increased risk of adverse outcomes than use of clopidogrel without PPI, suggesting that use of PPI may be associated with attenuation of benefits of clopidogrel after ACS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
Partial residuals for the proportional hazards regression model
SCHOENFELD, D. (1982) · Biometrika · doi:10.1093/biomet/69.1.239 · Cited by 3,111
Steinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809171 · Cited by 2,497
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Méneveau, N., Steg, P. G., Ferrières, J., Danchin, N., & Becquemont, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808227 · Cited by 1,728
Matetzky, S., Shenkman, B., Guetta, V., Shechter, M., Beinart, R., Goldenberg, I., Novikov, I., Pres, H., Savion, N., Varon, D., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130846.46168.03 · Cited by 1,354
Kennedy, L. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70021-0 · Cited by 1,195
Ho, P. M., Rumsfeld, J. S., Masoudi, F. A., McClure, D. L., Plomondon, M. E., Steiner, J. F., & Magid, D. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1836 · Cited by 1,135
Self-citation
Cited by
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182776f83 · Cited by 2,410
Kushner, F. G., Hand, M., Smith, S. C., King, S. B., Anderson, J. L., Antman, E. M., Bailey, S. R., Bates, E. R., Blankenship, J. C., Casey, D. E., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.015 · Cited by 1,911
Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease
Katz, P. O., Gerson, L. B., & Vela, M. F. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.444 · Cited by 1,767
Kushner, F. G., Hand, M., Smith, S. C., King, S. B., Anderson, J. L., Antman, E. M., Bailey, S. R., Bates, E. R., Blankenship, J. C., Casey, D. E., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192663 · Cited by 1,700
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.013 · Cited by 1,555
Shuldiner, A. R. (2009) · JAMA · doi:10.1001/jama.2009.1232 · Cited by 1,505
Malfertheiner, P., Chan, F. K., & McColl, K. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60938-7 · Cited by 1,488
Clopidogrel with or without Omeprazole in Coronary Artery Disease
Bhatt, D. L., Cryer, B. L., Contant, C. F., Cohen, M., Lanas, A., Schnitzer, T. J., Shook, T. L., Lapuerta, P., Goldsmith, M. A., Laine, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007964 · Cited by 1,240
Barkun, A. N., Bardou, M., Kuipers, E. J., Sung, J., Hunt, R. H., Martel, M., Sinclair, P., & for the International Consensus Upper Gastrointestinal Bleeding Conference Group* (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-2-201001190-00009 · Cited by 1,163
2012 Writing Committee Members, Jneid, H., Anderson, J. L., Wright, R. S., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318256f1e0 · Cited by 1,090
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.014 · Cited by 960
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318277d6a0 · Cited by 845
Gralnek, I., Dumonceau, J.-M., Kuipers, E., Lanas, A., Sanders, D., Kurien, M., Rotondano, G., Hucl, T., Dinis-Ribeiro, M., Marmo, R., et al. (2015) · Endoscopy · doi:10.1055/s-0034-1393172 · Cited by 828
O'Donoghue, M. L., Braunwald, E., Antman, E. M., Murphy, S. A., Bates, E. R., Rozenman, Y., Michelson, A. D., Hautvast, R. W., Ver Lee, P. N., Close, S. L., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61525-7 · Cited by 725
Sostres, C., Gargallo, C. J., Arroyo, M. T., & Lanas, A. (2010) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2009.11.005 · Cited by 685
Micromotor-enabled active drug delivery for in vivo treatment of stomach infection
de Ávila, B. E.-F., Angsantikul, P., Li, J., Angel Lopez-Ramirez, M., Ramírez-Herrera, D. E., Thamphiwatana, S., Chen, C., Delezuk, J., Samakapiruk, R., Ramez, V., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00309-w · Cited by 638
Complications of Proton Pump Inhibitor Therapy
Vaezi, M. F., Yang, Y.-X., & Howden, C. W. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.04.047 · Cited by 482
Jneid, H., Anderson, J. L., Wright, R. S., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Lincoff, A. M., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.06.004 · Cited by 479
Writing Committee Members, Abraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., Furberg, C. D., Johnson, D. A., Kahi, C. J., et al. (2010) · Circulation · doi:10.1161/cir.0b013e318202f701 · Cited by 451
Antiplatelet therapies for the treatment of cardiovascular disease
Michelson, A. D. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2957 · Cited by 407
Hulot, J.-S., Collet, J.-P., Silvain, J., Pena, A., Bellemain-Appaix, A., Barthélémy, O., Cayla, G., Beygui, F., & Montalescot, G. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.071 · Cited by 383
2011 Writing Group Members, Wright, R. S., Anderson, J. L., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Jneid, H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820f2f3e · Cited by 357
Wright, R. S., Anderson, J. L., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Jneid, H., Lincoff, A. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.009 · Cited by 342
Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population
Shah, N. H., LePendu, P., Bauer-Mehren, A., Ghebremariam, Y. T., Iyer, S. V., Marcus, J., Nead, K. T., Cooke, J. P., & Leeper, N. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0124653 · Cited by 335
Overutilization of proton-pump inhibitors: what the clinician needs to know
Heidelbaugh, J. J., Kim, A. H., Chang, R., & Walker, P. C. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12437358 · Cited by 327
Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update
Wedemeyer, R.-S., & Blume, H. (2014) · Drug Safety · doi:10.1007/s40264-014-0144-0 · Cited by 310
Kumbhani, D. J., Cannon, C. P., Beavers, C. J., Bhatt, D. L., Cuker, A., Gluckman, T. J., Marine, J. E., Mehran, R., Messe, S. R., Patel, N. S., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.011 · Cited by 308
Adverse Effects of Long-Term Proton Pump Inhibitor Therapy
Sheen, E., & Triadafilopoulos, G. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1560-3 · Cited by 307
Huber, K., Andreotti, F., Arnesen, H., Airaksinen, K. J., Cuisset, T., Kirchhof, P., Marín, F., & Lip, G. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-08-0580 · Cited by 303
2007 WRITING COMMITTEE MEMBERS, Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828478ac · Cited by 272
Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
Kinoshita, Y., Ishimura, N., & Ishihara, S. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18001 · Cited by 271
Charlot, M., Ahlehoff, O., Norgaard, M. L., Jørgensen, C. H., Sørensen, R., Abildstrøm, S. Z., Hansen, P. R., Madsen, J. K., Køber, L., Torp-Pedersen, C., et al. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-6-201009210-00005 · Cited by 264
Scott, S. A., Sangkuhl, K., Shuldiner, A. R., Hulot, J.-S., Thorn, C. F., Altman, R. B., & Klein, T. E. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834d4962 · Cited by 261
Deodhar, M., Al Rihani, S. B., Arwood, M. J., Darakjian, L., Dow, P., Turgeon, J., & Michaud, V. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090846 · Cited by 261
Ghebremariam, Y. T., LePendu, P., Lee, J. C., Erlanson, D. A., Slaviero, A., Shah, N. H., Leiper, J., & Cooke, J. P. (2013) · Circulation · doi:10.1161/circulationaha.113.003602 · Cited by 255
The risks of long-term use of proton pump inhibitors: a critical review
Jaynes, M., & Kumar, A. B. (2019) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098618809927 · Cited by 254
Blood Pressure–Lowering Effect of Orally Ingested Nitrite Is Abolished by a Proton Pump Inhibitor
Montenegro, M. F., Sundqvist, M. L., Larsen, F. J., Zhuge, Z., Carlström, M., Weitzberg, E., & Lundberg, J. O. (2017) · Hypertension · doi:10.1161/hypertensionaha.116.08081 · Cited by 102
Metadata
- Authors
- Ho, P. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-03-04
- Volume
- 301
- Issue
- 9
- Pages
- 937
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2143777566
- Cited by
- 1,007
- References
- 32
- FWCI
- 121.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.